Meca-Lallana, J., Ayuso, T., Martinez-Yelamos, S., Duran, C., Martin, Y., Navarro, N., . . . Ricart, J. (2020). Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Citación estilo ChicagoMeca-Lallana, J., et al. Effectiveness of Fingolimod Versus Natalizumab As Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study. 2020.
Cita MLAMeca-Lallana, J., et al. Effectiveness of Fingolimod Versus Natalizumab As Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study. 2020.
Precaución: Estas citas no son 100% exactas.